{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:58:43Z","timestamp":1790614723497,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcineurin inhibitors (CNIs) are associated with nephrotoxicity, endothelial cell dysfunction, and thrombotic microangiopathy (TMA). Evolving evidence suggests an important role for complement dysregulation in the pathogenesis of CNI-induced TMA. However, the exact mechanism(s) of CNI-induced TMA remain(s) unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using blood outgrowth endothelial cells (BOECs) from healthy donors, we evaluated the effects of cyclosporine on endothelial cell integrity. Specifically, we determined complement activation (C3c and C9) and regulation (CD46, CD55, CD59, and complement factor H [CFH] deposition) as these occurred on the endothelial cell surface membrane and glycocalyx.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that exposing the endothelium to cyclosporine resulted in a dose- and time-dependent enhancement of complement deposition and cytotoxicity. We, therefore, employed flow cytometry, Western blotting\/CFH cofactor assays, and immunofluorescence imaging to determine the expression of complement regulators and the functional activity and localization of CFH. Notably, while cyclosporine led to the upregulation of complement regulators CD46, CD55, and CD59 on the endothelial cell surface, it also diminished the endothelial cell glycocalyx through the shedding of heparan sulfate side chains. The weakened endothelial cell glycocalyx resulted in decreased CFH surface binding and surface cofactor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our findings confirm a role for complement in cyclosporine-induced endothelial injury and suggest that decreased glycocalyx density, induced by cyclosporine, is a mechanism that leads to complement alternative pathway dysregulation\n                      <jats:italic>via<\/jats:italic>\n                      decreased CFH surface binding and cofactor activity. This mechanism may apply to other secondary TMAs\u2014in which a role for complement has so far not been recognized\u2014and provide a potential therapeutic target and an important marker for patients on calcineurin inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2023.891513","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T01:19:05Z","timestamp":1676251145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The loss of glycocalyx integrity impairs complement factor H binding and contributes to cyclosporine-induced endothelial cell injury"],"prefix":"10.3389","volume":"10","author":[{"given":"Chia Wei","family":"Teoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Riedl Khursigara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina G.","family":"Ortiz-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlette","family":"Bohorquez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer A.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"B1","first-page":"478A","article-title":"The association of von Willebrand factor and the alternative complement pathway in atypical hemolytic uremic syndrome - complement amplifying or protective?","volume":"25","author":"Noone","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ejim.2013.05.009","article-title":"Complement activation in diseases presenting with thrombotic microangiopathy","volume":"24","author":"Meri","year":"2013","journal-title":"Eur J Internal Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.amjmed.2012.09.006","article-title":"Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome","volume":"126","author":"Tsai","year":"2013","journal-title":"Am J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","article-title":"Complement and coagulation: strangers or partners in crime?","volume":"28","author":"Markiewski","year":"2007","journal-title":"Trends Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.transci.2016.04.012","article-title":"The alternative pathway of complement and the thrombotic microangiopathies","volume":"54","author":"Teoh","year":"2016","journal-title":"Transfus Apher Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","article-title":"Secondary atypical hemolytic uremic syndromes in the era of complement blockade","volume":"95","author":"Praga","year":"2019","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement (Part 2)","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodriguez de Cordoba","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele","year":"2014","journal-title":"Seminars Immunopathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"92","author":"Brocklebank","year":"2017","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","article-title":"Antibody mediated rejection associated with complement factor H-related protein 3\/1 deficiency successfully treated with Eculizumab","volume":"12","author":"Noone","year":"2012","journal-title":"Am J Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant."},{"key":"B23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nri3225","article-title":"The role of complement in the early immune response to transplantation","volume":"12","author":"Sacks","year":"2012","journal-title":"Nat Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/ndt\/gft488","article-title":"Ischaemia-reperfusion injury: a major protagonist in kidney transplantation","volume":"29","author":"Ponticelli","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"27915","DOI":"10.1038\/srep27915","article-title":"Calcineurin inhibitors cyclosporine a and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling","volume":"6","author":"Rodrigues-Diez","year":"2016","journal-title":"Sci Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00109-014-1173-y","article-title":"Graft microvascular disease in solid organ transplantation","volume":"92","author":"Jiang","year":"2014","journal-title":"J Mol Med (Berl)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","author":"Cortina","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.transproceed.2005.02.112","article-title":"Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy","volume":"37","author":"Bren","year":"2005","journal-title":"Transplant Proc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","article-title":"Cyclosporine-associated thrombotic microangiopathy in renal allografts","volume":"55","author":"Zarifian","year":"1999","journal-title":"Kidney Int."},{"key":"B32","first-page":"1321","article-title":"Renal transplant pathology","author":"Nickeleit","year":"2015","journal-title":"Heptinstall Pathology of the Kidney"},{"key":"B33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5414\/CNP67335","article-title":"De novo thrombotic microangiopathy. An underrated complication of renal transplantation","volume":"67","author":"Ponticelli","year":"2007","journal-title":"Clin Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3349\/ymj.2007.48.3.517","article-title":"Activation of intrarenal complement system in mouse model for chronic cyclosporine nephrotoxicity","volume":"48","author":"Kim","year":"2007","journal-title":"Yonsei Med J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","article-title":"Von Willebrand factor regulates complement on endothelial cells","volume":"90","author":"Noone","year":"2016","journal-title":"Kidney Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/nprot.2012.093","article-title":"Establishment of outgrowth endothelial cells from peripheral blood","volume":"7","author":"Martin-Ramirez","year":"2012","journal-title":"Nat Protocols."},{"key":"B38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2016.08.015","article-title":"Complement activation induces neutrophil adhesion and neutrophil-platelet aggregate formation on vascular endothelial cells","volume":"2","author":"Riedl","year":"2017","journal-title":"Kidney Int Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/blood-2015-11-680009","article-title":"Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome","volume":"127","author":"Hyvarinen","year":"2016","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1681\/ASN.2006091069","article-title":"Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells","volume":"18","author":"Heinen","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.4049\/jimmunol.168.12.6298","article-title":"Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells","volume":"168","author":"Barilla-LaBarca","year":"2002","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.156.11.4415","article-title":"Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement","volume":"156","author":"Liszewski","year":"1996","journal-title":"J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1242\/jcs.124388","article-title":"The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation","volume":"126","author":"Triantafilou","year":"2013","journal-title":"J Cell Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/jth.12160","article-title":"Weibel-Palade bodies: a window to von Willebrand disease","volume":"11","author":"Valentijn","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.carpath.2004.03.495","article-title":"The Tie2-ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies","volume":"13","author":"Fiedler","year":"2004","journal-title":"Cardiovasc Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1084\/jem.188.9.1751","article-title":"Rapid secretion of prestored interleukin 8 from Weibel-palade bodies of microvascular endothelial cells","volume":"188","author":"Utgaard","year":"1998","journal-title":"J Exp Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00467-017-3744-y","article-title":"The role of von Willebrand factor in thrombotic microangiopathy","volume":"33","author":"Noone","year":"2017","journal-title":"Pediatr Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1021\/bi4003452","article-title":"Functional anatomy of complement factor H","volume":"52","author":"Makou","year":"2013","journal-title":"Biochemistry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molimm.2004.02.005","article-title":"The human complement factor H: functional roles, genetic variations and disease associations","volume":"41","author":"Rodriguez de Cordoba","year":"2004","journal-title":"Mol Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2249.2007.03553.x","article-title":"Translational mini-review series on complement factor H: structural and functional correlations for factor H","volume":"151","author":"Schmidt","year":"2008","journal-title":"Clin Exp Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1042\/BST0381342","article-title":"Complement factor H and age-related macular degeneration: the role of glycosaminoglycan recognition in disease pathology","volume":"38","author":"Clark","year":"2010","journal-title":"Biochem Soc Trans."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.4049\/jimmunol.1201751","article-title":"Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions","volume":"190","author":"Clark","year":"2013","journal-title":"J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4049\/jimmunol.122.1.75","article-title":"Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and \u03b21H for cell-bound C3b","volume":"122","author":"Kazatchkine","year":"1979","journal-title":"J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.4049\/jimmunol.181.4.2610","article-title":"A new map of glycosaminoglycan and C3b binding sites on factor H","volume":"181","author":"Schmidt","year":"2008","journal-title":"J Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"31471","DOI":"10.1074\/jbc.M112.380386","article-title":"Factor H and properdin recognize different epitopes on renal tubular epithelial heparan sulfate","volume":"287","author":"Zaferani","year":"2012","journal-title":"J Biol Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1042\/CBI20100670","article-title":"VEGF increases the proliferative capacity and eNOS\/NO levels of endothelial progenitor cells through the calcineurin\/NFAT signalling pathway","volume":"36","author":"Yang","year":"2012","journal-title":"Cell Biol Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ncpneph0225","article-title":"Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts","volume":"2","author":"Liptak","year":"2006","journal-title":"Nat Clin Practice Nephrol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2249.1993.tb03446.x","article-title":"Activation of human complement by mouse and mouse\/human chimeric monoclonal antibodies","volume":"94","author":"Seino","year":"1993","journal-title":"Clin Exp Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist","volume":"2","author":"Schiff","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"25196","DOI":"10.1074\/jbc.M110.119446","article-title":"Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development","volume":"285","author":"Basu","year":"2010","journal-title":"J Biol Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"F160","DOI":"10.1152\/ajprenal.90567.2008","article-title":"Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death","volume":"296","author":"Bouvier","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.athoracsur.2004.08.078","article-title":"Cyclosporine modulates the response to hypoxia-reoxygenation in pulmonary artery endothelial cells","volume":"79","author":"Farivar","year":"2005","journal-title":"Annals Thoracic Surg."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e0175242","DOI":"10.1371\/journal.pone.0175242","article-title":"Cyclosporine a alters expression of renal microRNAs: new insights into calcineurin inhibitor nephrotoxicity","volume":"12","author":"Gooch","year":"2017","journal-title":"PLoS ONE."},{"key":"B64","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1159\/000350614","article-title":"Cyclosporine attenuates arginine transport, in human endothelial cells, through modulation of cationic amino acid transporter-1","volume":"37","author":"Grupper","year":"2013","journal-title":"Am J Nephrol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.891513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T01:19:09Z","timestamp":1676251149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.891513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":64,"alternative-id":["10.3389\/fmed.2023.891513"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.891513","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"891513"}}